Document Detail


A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group.
MedLine Citation:
PMID:  1988829     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Despite the use of vidarabine, herpes simplex virus (HSV) infection in neonates continues to be a disease of high morbidity and mortality. We undertook a controlled trial comparing vidarabine with acyclovir for the treatment of neonatal HSV infection. METHODS: Babies less than one month of age with virologically confirmed HSV infection were randomly and blindly assigned to receive either intravenous vidarabine (30 mg per kilogram of body weight per day; n = 95) or acyclovir (30 mg per kilogram per day; n = 107) for 10 days. Actuarial rates of mortality and morbidity among the survivors after one year were compared overall and according to the extent of the disease at entry into the study (infection confined to the skin, eyes, or mouth; encephalitis; or disseminated disease). RESULTS: After adjustment for differences between groups in the extent of disease, there was no difference between vidarabine and acyclovir in either morbidity (P = 0.83) or mortality (P = 0.27). None of the 85 babies with disease confined to the skin, eyes, or mouth died. Of the 31 babies in this group who were treated with vidarabine and followed for a year, 88 percent (22 of 25) were judged to be developing normally after one year, as compared with 98 percent (45 of 46) of the 54 treated with acyclovir (95 percent confidence interval for the difference, -4 to 24). For the 71 babies with encephalitis, mortality was 14 percent with vidarabine (5 of 36) and with acyclovir (5 of 35); of the survivors, 43 percent (13 of 30) and 29 percent (8 of 28), respectively, were developing normally after one year (95 percent confidence interval for the difference, -11 to 39). For the 46 babies with disseminated disease, mortality was 50 percent (14 of 28) with vidarabine and 61 percent (11 of 18) with acyclovir (95 percent confidence interval for the difference, -20 to 40); of the survivors, 58 percent (7 of 12) and 60 percent (3 of 5), respectively, were judged to be developing normally after one year (95 percent confidence interval for the difference, -40 to 50). Both medications were without serious toxic effects. CONCLUSIONS: In this multicenter, randomized, blinded study there were no differences in outcome between vidarabine and acyclovir in the treatment of neonatal HSV infection. The study lacked statistical power to determine whether there were sizable differences within the subgroups of those with localized HSV, encephalitis, or disseminated disease.
Authors:
R Whitley; A Arvin; C Prober; S Burchett; L Corey; D Powell; S Plotkin; S Starr; C Alford; J Connor
Related Documents :
7949499 - Implementation and evaluation of a standardized herpes simplex virus prophylaxis protoc...
2727629 - Treatment of tuberculous meningitis in adults with a combination of isoniazid, rifampic...
9722899 - Outbreak of varicella in a pediatric oncology unit.
6277999 - Ketoconazole in griseofulvin-resistant dermatophytosis.
15030339 - Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis.
20482459 - Screening for latent tuberculosis infection in south korean healthcare workers using a ...
10190599 - Long-term functional results of wrist arthrodesis in rheumatoid arthritis.
10917349 - Microsurgical treatment of symptomatic sacral tarlov cysts.
22525939 - Effect of different statistical methods on union or time to union in a published study ...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  The New England journal of medicine     Volume:  324     ISSN:  0028-4793     ISO Abbreviation:  N. Engl. J. Med.     Publication Date:  1991 Feb 
Date Detail:
Created Date:  1991-02-27     Completed Date:  1991-02-27     Revised Date:  2010-03-24    
Medline Journal Info:
Nlm Unique ID:  0255562     Medline TA:  N Engl J Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  444-9     Citation Subset:  AIM; IM    
Affiliation:
Department of Pediatrics, University of Alabama, Birmingham.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acyclovir / administration & dosage,  therapeutic use*
Encephalitis / drug therapy
Female
Herpes Simplex / drug therapy*,  mortality
Humans
Infant, Newborn
Injections, Intravenous
Male
Recurrence
Vidarabine / administration & dosage,  therapeutic use*
Grant Support
ID/Acronym/Agency:
N01-AI-62554/AI/NIAID NIH HHS; RR-032/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
5536-17-4/Vidarabine; 59277-89-3/Acyclovir

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Diagnostic relevance of clonal cytogenetic aberrations in malignant soft-tissue tumors.
Next Document:  Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National...